FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 675 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How does processed and red meat cause cancer and how much... March 17, 2021 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 Hugh Jackman Stops His Show To Bring Woman With Breast Cancer... August 26, 2019 When You Lose a Spouse to Cancer and Need Support February 25, 2021 Load more HOT NEWS Gym Offers Free Membership & Support To Those Struggling With Addiction EMA Recommends Granting a Marketing Authorisation for Equidacent Scientists Focus on Fusion Proteins in Childhood Cancers ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration...
